NOVN - ノバン (Novan Inc.)


   Novartis-Aktie: Rückschlag  2021/06/12 20:00:18 BORSE ONLINE
Der Schweizer Pharmakonzern Novartis hat mehrere klinische Studien zu seinem Augenmedikament Beovu abgebrochen. Grund seien höhere Raten von intraokularen Entzündungen als bei der Vergleichstherapie. Von Sven Parplies, Euro am Sonntag
   Biosimilar of Remicade Market Future Trends, Revenue Growth, Profitability & Leading Players| Key players- Synthon Pharmaceuticals, LG Life Sciences, Novartis (Sandoz), etc.  2021/06/12 09:00:41 Jumbo News
Biosimilar of Remicade Market to 2027: Deep Analysis The report offers a complete research study of the global Biosimilar of Remicade Market that includes accurate forecasts and analysis at global, regional, and country levels. It provides a comprehensive view of the global Biosimilar of Remicade Market and detailed value chain analysis to help players to []
   Glaucoma Treatment Market Current Status, In-depth Analysis and Forecast 2021-2026 : Novartis AG, Allergan, Merck & Co. Inc., Akorn Inc.  2021/06/12 02:30:51 Jumbo News
Pixion Market Research new study, Glaucoma Treatment Market Report 2021 provides an analytical assessment of the primary challenges faced by this market currently and in the coming years. The insights of the subject matter presented in the report will help market players in understanding the problems they may face while operating in this market over []
   The Buzz Show: Novan, Inc. (NASDAQ: NOVN) Surges Upon Announcement of Positive Preclinical Data  2021/06/11 20:42:29 Financial Buzz
FinancialBuzz.coms latest The Buzz Show: Featuring Our Corporate News Recap on Novan, Inc. Surges Upon Announcement of Positive Preclinical Data Novan, Inc. (NASDAQ: NOVN) surged over 60% in premarket trading after the company announced positive topline efficacy and safety results for the B-SIMPLE4 pivotal Phase 3 clinical study of SB206 There are currently no U.S. The post The Buzz Show: Novan, Inc. (NASDAQ: NOVN) Surges Upon Announcement of Positive Preclinical Data first appeared on Financial Buzz .
   FDA grants accelerated approval to capmatinib for metastatic non-small cell lung cancer  2021/06/11 18:07:09 US Food and Drug Administration
FDA granted accelerated approval to capmatinib (TABRECTATM, Novartis) for adult patients with metastatic non-small cell lung cancer whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test.
   Eli Lil­ly Aban­dons IL-23 Psoriasis Program, Instead Will Focus On Ulcerative Colitis, Crohn's Disease Indications  2021/04/27 18:34:25 Benzinga
Tucked in its Q1 earnings release, Eli Lilly And Co (NYSE: LLY ) has scrapped its plans to seek approval for mirikizumab in psoriasis . The company decided not to enter the market despite the anti-IL-23p19 antibody outperforming Novartis AG’s (NYSE: NVS ) Cosentyx in a Phase 3 trial last year . AbbVie Inc’s (NYSE: ABBV ) anti-IL-23 antibody Skyrizi and Johnson & Johnson’s (NYSE:
   Truffa Farmaci Lombardia, 5 ospedali San Donato patteggiano, a giudizio Bayer e Novartis  2021/04/27 12:36:25 Italy
   Novartis Q1 sales, profit miss analyst expectations amid COVID-19 impact  2021/04/27 06:30:27
   Outlook on the Digital Respiratory Devices Global Market to 2030 - Focus on Sensors, Smart Inhalers & Nebulizers, Application, Countries and Competitive Landscape  2021/04/19 17:45:00 Benzinga
DUBLIN , April 19, 2021 /PRNewswire/ -- The "Global Digital Respiratory Devices Market 2021-2030: Focus on Sensors, Smart Inhalers & Nebulizers, Application, 9 Countries' Data, and Competitive Landscape" report has been added to's offering. The Global Digital Respiratory Devices Market is projected to reach $405.1 million by 2030. The study highlights that the market is set to witness a CAGR of 27.31% between 2021 and 2030. This comprehensive study of the global digital respiratory devices market covers the following: Market numbers on product types More than 35 key products present in the market Market share analysis for the global digital respiratory devices Market and its indications Detailed global and regional market share analysis Besides these parameters, the study also encompasses the market growth drivers, opportunities, market restraining factors, competition mapping, end-user analysis, and COVID-19 impact on the market. The study indicates that increasing prevalence of respiratory diseases, increasing adoption of digital technology among individuals, and treatment satisfaction with inhaled therapy among individuals are fueling the growth of the market.
   Novartis Taps Artios In Discovery Pact To Enhance Radioligand Portfolio  2021/04/07 11:08:04 Benzinga
Novartis AG (NYSE: NVS ) has struck a deal with UK-based Artios Pharma to access DNA damage response (DDR) targets that can potentially enhance its radioligand therapies. Artios is set to get $20 million upfront and up to $1.3 billion in milestones in return for the targets. During the three-year collaboration, Artios and Novartis will … Full story available on
   Ark Funds, Illumina Invest In SomaLogic SPAC Deal: What Investors Should Know  2021/03/29 15:16:06 Benzinga
A leader in the proteomics field is going public with a SPAC deal announced Monday. The SPAC Deal: SomaLogic announced a SPAC deal with CM Life Sciences II Inc (NASDAQ: CMIIU ), valuing the company at $1.2 billion. A $375 million PIPE on the SPAC merger includes investments from SoftBank Group Corp (OTC: SFTBY ), T. Rowe Price, Illumina, Inc. (NASDAQ: ILMN ), Novartis AG (NYSE: NVS ) and accounts advised by Ark Invest. Kevin Conroy, the CEO of EXACT Sciences Corporation (NASDAQ: EXAS ) will join the board of directors after the merger is complete. Current shareholders of CM Life Sciences II will own 14% of the company after the merger. PIPE investors will own 20% of the company after the merger. About SomaLogic: Using … Full story available on
   Novartis corrects chairman's comments about kickbacks case  2021/03/24 15:30:28
   Novartis’ $2B cancer drug spurs ‘groundbreaking’ PhIII data for prostate cancer  2021/03/23 13:11:17 Endpoints News
Continuing a streak of upbeat announcements on its radioligand portfolio, Novartis says that their Phase III study of 177Lu-PSMA-617 hit both co-primary endpoints on overall survival and radiographic progression-free survival for prostate cancer patients — setting up a likely approval some analysts believe would be worth more than a billion
   Autoinjectors Market Is Expected To Exhibit 18.1% CAGR By 2027 | Novartis AG, SHL Medical, Eli Lilly and Company  2021/03/23 12:54:31 OpenPR
Rise in anaphylaxis cases and increases in R&D activities by key players in the market are anticipated to drive the market. Rapid growth has been observed in adoption of biosimilars over branded drugs, which provides low cost treatment options for
   Rizatriptan Benzoate Market Trends and Growth by 2021-2026 | Merck, Pfizer, Roche, GSK, Mylan, TEVA, Novartis  2021/03/23 11:51:30 OpenPR
The global Rizatriptan Benzoate market size is projected to grow in the historic period resulted from economic growth in emerging markets, the rise in awareness of the benefits and developed nations towards Rizatriptan Benzoate costs and increasing production and growing